Structure Therapeutics Inc
NASDAQ:GPCR
Intrinsic Value
The intrinsic value of one GPCR stock under the Base Case scenario is 15.41 USD. Compared to the current market price of 23.86 USD, Structure Therapeutics Inc is Overvalued by 35%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Structure Therapeutics Inc
Fundamental Analysis

Revenue & Expenses Breakdown
Structure Therapeutics Inc
Balance Sheet Decomposition
Structure Therapeutics Inc
Current Assets | 891.2m |
Cash & Short-Term Investments | 883.5m |
Other Current Assets | 7.7m |
Non-Current Assets | 12.1m |
PP&E | 7m |
Other Non-Current Assets | 5.1m |
Free Cash Flow Analysis
Structure Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Structure Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-158.2m
USD
|
Operating Income
|
-158.2m
USD
|
Other Expenses
|
35.7m
USD
|
Net Income
|
-122.5m
USD
|
GPCR Profitability Score
Profitability Due Diligence
Structure Therapeutics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
Score
Structure Therapeutics Inc's profitability score is 28/100. The higher the profitability score, the more profitable the company is.
GPCR Solvency Score
Solvency Due Diligence
Structure Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Structure Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
GPCR Price Targets Summary
Structure Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for GPCR is 80.29 USD with a low forecast of 50.5 USD and a high forecast of 123.9 USD.
Dividends
Current shareholder yield for GPCR is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one GPCR stock under the Base Case scenario is 15.41 USD.
Compared to the current market price of 23.86 USD, Structure Therapeutics Inc is Overvalued by 35%.